$630 Billion is the total value of Rhenman & Partners Asset Management AB's 107 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 26.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Sell | Alexion Pharmaceuticals Inc | $19,814,963,000 | +75973.9% | 161,702 | -27.5% | 3.15% | -32.0% |
| CELG | Sell | Celgene Corp | $19,442,580,000 | +98960.4% | 186,000 | -6.5% | 3.09% | -11.4% |
| BIIB | Sell | Biogen Inc | $17,842,710,000 | +92129.5% | 57,000 | -28.8% | 2.83% | -17.5% |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $12,952,800,000 | +110892.3% | 140,000 | -6.7% | 2.06% | -0.7% |
| REGN | Sell | Regeneron Pharmaceuticals | $11,859,590,000 | +68504.1% | 29,500 | -40.4% | 1.88% | -38.6% |
| CI | Sell | Cigna Corp | $10,946,880,000 | +86293.2% | 84,000 | -15.2% | 1.74% | -22.7% |
| ABMD | Sell | Abiomed Inc | $10,929,300,000 | +95144.4% | 85,000 | -19.0% | 1.74% | -14.8% |
| AMGN | Sell | Amgen Inc | $9,174,550,000 | +97950.1% | 55,000 | -10.6% | 1.46% | -12.3% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $8,811,400,000 | +81328.7% | 130,000 | -33.3% | 1.40% | -27.2% |
| ESRX | Sell | Express Scripts Holding Co | $7,828,830,000 | +88934.8% | 111,000 | -4.3% | 1.24% | -20.4% |
| EXEL | Sell | Exelixis Inc | $7,674,000,000 | +122723.3% | 600,000 | -25.0% | 1.22% | +9.9% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $7,288,800,000 | +73583.8% | 60,000 | -14.3% | 1.16% | -34.1% |
| ENDP | Sell | Endo International Plc | $7,258,030,000 | +73191.2% | 360,200 | -43.3% | 1.15% | -34.5% |
| NKTR | Sell | Nektar Therapeutics | $6,700,200,000 | +100082.4% | 390,000 | -17.0% | 1.06% | -10.4% |
| SUPN | Sell | Supernus Pharmaceuticals Inc | $6,677,100,000 | +116960.0% | 270,000 | -3.6% | 1.06% | +4.7% |
| EW | Sell | Edwards Lifesciences Corp | $6,630,800,000 | +94883.5% | 55,000 | -21.4% | 1.05% | -15.1% |
| HZNP | Sell | Horizon Pharma Plc | $6,617,450,000 | +108489.6% | 365,000 | -1.4% | 1.05% | -2.9% |
| CNC | Sell | Centene Corp | $5,356,800,000 | +67086.8% | 80,000 | -28.4% | 0.85% | -39.9% |
| WBA | Sell | Walgreens Boots Alliance Inc | $5,240,300,000 | +96264.5% | 65,000 | -0.5% | 0.83% | -13.9% |
| NVRO | Sell | Nevro Corp | $5,146,427,000 | +128400.0% | 49,300 | -9.2% | 0.82% | +14.9% |
| AET | Sell | Aetna Inc | $4,848,900,000 | +59155.8% | 42,000 | -37.3% | 0.77% | -47.0% |
| OMCL | Sell | Omnicell Inc | $4,539,967,000 | +103081.1% | 118,537 | -7.8% | 0.72% | -7.7% |
| HUM | Sell | Humana Inc | $4,422,250,000 | +81854.2% | 25,000 | -16.7% | 0.70% | -26.7% |
| ABC | Sell | Amerisourcebergen Corp | $4,281,340,000 | +69099.0% | 53,000 | -32.1% | 0.68% | -38.1% |
| CAH | Sell | Cardinal Health Inc | $4,273,500,000 | +66704.8% | 55,000 | -32.9% | 0.68% | -40.2% |
| MCK | Sell | Mckesson Corp | $4,168,750,000 | +74342.0% | 25,000 | -16.7% | 0.66% | -33.4% |
| LH | Sell | Laboratory Crp Of Amer Hldgs | $4,124,400,000 | +70258.2% | 30,000 | -33.3% | 0.66% | -37.1% |
| RDUS | Sell | Radius Health Inc | $4,056,750,000 | +110287.8% | 75,000 | -25.0% | 0.64% | -1.4% |
| CEMP | Sell | Cempra Inc | $3,896,200,000 | +138063.1% | 161,000 | -5.8% | 0.62% | +23.6% |
| COO | Sell | Cooper Cos Inc/The | $3,585,200,000 | +83490.6% | 20,000 | -20.0% | 0.57% | -25.3% |
| RVNC | Sell | Revance Therapeutics Inc | $3,404,100,000 | +113673.4% | 210,000 | -4.5% | 0.54% | +1.9% |
| PODD | Sell | Insulet Corp | $2,333,580,000 | +93996.0% | 57,000 | -30.5% | 0.37% | -15.7% |
| FGEN | Sell | Fibrogen Inc | $2,152,800,000 | +114961.5% | 104,000 | -8.8% | 0.34% | +3.0% |
| ESPR | Sell | Esperion Therapeutics Inc | $1,800,500,000 | +130088.0% | 130,000 | -7.1% | 0.29% | +16.3% |
| VRX | Sell | Valeant Pharmaceuticals Inte | $1,227,500,000 | +28925.8% | 50,000 | -76.2% | 0.20% | -74.0% |
| RGLS | Sell | Regulus Therapeutics Inc | $990,000,000 | +97726.1% | 300,000 | -14.3% | 0.16% | -12.8% |
| CATB | Sell | Catabasis Pharmaceuticals In | $616,000,000 | +48138.1% | 100,000 | -71.0% | 0.10% | -56.8% |
| MD | Sell | Mednax Inc | $596,250,000 | +10190.8% | 9,000 | -88.8% | 0.10% | -90.8% |
| RARE | Exit | Ultragenyx Pharmaceutical Inc | $0 | – | -10,000 | -100.0% | -0.09% | – |
| OREX | Exit | Orexigen Therapeutics Inc | $0 | – | -1,200,000 | -100.0% | -0.09% | – |
| QHCCQ | Exit | Quorum Health Corp | $0 | – | -56,250 | -100.0% | -0.11% | – |
| CYH | Exit | Community Health Syst Inc | $0 | – | -175,000 | -100.0% | -0.38% | – |
| BDX | Exit | Becton Dickinson & Co | $0 | – | -15,000 | -100.0% | -0.45% | – |
| ABT | Exit | Abbott Laboratories | $0 | – | -84,100 | -100.0% | -0.59% | – |
| LIVN | Exit | Livanova Plc | $0 | – | -70,000 | -100.0% | -0.62% | – |
| CERN | Exit | Cerner Corp | $0 | – | -81,000 | -100.0% | -0.84% | – |
| MDVN | Exit | Medivation Inc | $0 | – | -80,000 | -100.0% | -0.86% | – |
| ANTM | Exit | Anthem Inc | $0 | – | -40,000 | -100.0% | -0.93% | – |
| CPHD | Exit | Cepheid Inc | $0 | – | -260,000 | -100.0% | -1.42% | – |
| MDT | Exit | Medtronic Plc | $0 | – | -127,000 | -100.0% | -1.96% | – |
| PFE | Exit | Pfizer Inc | $0 | – | -375,000 | -100.0% | -2.34% | – |
| GILD | Exit | Gilead Sciences Inc | $0 | – | -240,000 | -100.0% | -3.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.